Over the last decade, therapeutic antibodies have fundamentally changed approaches in different areas of medicine, providing the impetus for a big leap forward in the treatment of cancers and autoimmune diseases. But could they also soon have a lasting impact on agriculture? Some pioneers predict that – in the near future – peptides, proteins and RNA will be driving markets in the fast-growing biopesticide and biostimulant sectors.
Enterprise Therapeutics: Vital service
AppointmentsEpidarex Capital-backed respiratory disease start-up Enterprise Therapeutics has named biotech entrepreneur John Ford as its new CEO. Ford previously co-founded Xention, Ario Pharma, and Metrion Biosciences.
Mediolanum licences Apeptico’s TNF peptide Solnatide
Latest NewsViennese Apeptico Forschung und Entwicklung GmbH and Milan-based Mediolanum Farmaceutici S.p.A. have signed a research & development cooperation and license agreement for Apeptico’s compound solnatide.
A fresh take on biotech?
Latest NewsFor the second time, biotech communication start-up Labiotech hosted its event LBRefresh, this year in Paris, France. Participants enjoyed panel discussions, a start-up battle and intimate fireside chats…
Biopesticides: Of strawberries and antibodies
BackgroundConfo Therapeutics: Time for change
AppointmentsConfo Therapeutics wants to metamorphose from a tech company to a drug discovery company, and it has hired Cedric Ververken to guide the transition.
Arquer Diagnostics: New head for Dx
AppointmentsNovo Nordisk: Passing the baton
AppointmentsLars Fruergaard Jørgensen, currently executive vice president and head of Corporate Development at Novo Nordisk, will take over the helm of the Danish diabetes major. He takes over from long-time CEO Lars Rebien Sørensen.
Bioplastics industry grapples with ignorant consumers
Latest NewsEU consumers have minor knowledge on bioplastics but unrealistically high expectations that can not be fulfilled, researchers said at 11th European Bioplastics Conference in Berlin.
Real World Data: Beyond clinical trials
BackgroundOnly a small fraction of carefully selected patients are allowed to enroll in randomised controlled trials involving new compounds – the gold standard of drug assessment. But trying to acquire the most significant efficacy and safety results for a new drug is one goal, treating patients every day in hospitals or practices with it is something else entirely. Discrepancies are inevitable. Now real-world data that’s been gathered in large observational studies is attempting to close the gap between experimental, artificial study settings and clinical realities.
Carbios tackles marine littering
Latest NewsFrench Carbios has presented a process that depolymerises one of the most common non-recycled plastics polluting the oceans.